207940 — Samsung Biologics Co Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩55tn
- KR₩55tn
- KR₩4tn
Annual cashflow statement for Samsung Biologics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 202,904 | 240,975 | 393,589 | 798,056 | 857,691 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -85,583 | 66,158 | 187,832 | 289,411 | 312,968 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -239,711 | -248,218 | -288,614 | -442,684 | 5,787 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 10,154 | 202,090 | 454,596 | 953,048 | 1,666,229 |
| Capital Expenditures | -181,196 | -148,566 | -421,152 | -1,009,226 | -1,105,325 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 520,838 | -270,120 | -512,337 | -2,097,252 | -460,981 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 339,642 | -418,686 | -933,489 | -3,106,477 | -1,566,305 |
| Financing Cash Flow Items | — | — | — | -12,430 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -239,806 | 122,560 | 496,622 | 3,000,080 | -635,050 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 107,479 | -96,251 | 18,560 | 843,409 | -522,882 |